NVO

Novo Nordisk A/S (NVO)

Last Price$86.30.8%
Market Cap$384.7B
LTM Return on Equity (ROE)
81.3%
5Y avg
74.5%
Biotechnology industry median
(51.8%)
Stock quality & Intrinsic value
7/10
(0.2%) overvalued

Novo Nordisk A/S Return on Equity (ROE)

Annual
Quarterly
LTM
Industry median
Company stand-alone
NVO
Healthcare
Crunching data... Almost there!
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Return on Equity (ROE)
18.9%
21.6%
22.4%
27.4%
29.6%
31.3%
39.6%
46.0%
54.9%
60.5%
63.9%
79.9%
82.2%
80.2%
76.0%
71.2%
69.7%
71.2%
72.0%
88.1%
NVO
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for NVO and see if it's the right time to invest.
Dive in

Novo Nordisk A/S (NVO) Return on Equity (ROE) comparison analysis

Crunching data... Almost there!

NVO key stats

USD
DKK
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms

FAQ

1) What is Novo Nordisk A/S's Return on Equity (ROE)?

As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 81.3%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Novo Nordisk A/S have been 75.8% over the past three years, and 78.2% over the past five years.

2) Is Novo Nordisk A/S's Return on Equity (ROE) Good?

As of today, Novo Nordisk A/S's Return on Equity (ROE) is 81.3%, which is higher than industry median of (51.8%). It indicates that Novo Nordisk A/S's Return on Equity (ROE) is Good.

3) How does Novo Nordisk A/S's Return on Equity (ROE) compare to its peers?

As of today, Novo Nordisk A/S's Return on Equity (ROE) is 81.3%, which is higher than peer median of (2.4%). The list of peers includes UTHR, GMAB, REGN, INCY, BNTX, VRTX, ARGX, MRNA, BGNE, ALNY.